Abiopharma

🔍 Arets Max (Executive)

Company: STANDEX INTERNATIONAL CORP/DE/ (SXI)

Report Date: 2026-08-21

Detailed Transactions and Holdings:

• Acquired 1 shares of Common Stock at $308.153 per share (Direct)
  Date: 2026-08-21 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,335.59 | transaction_form_type: 4 | Footnotes: F1
• Acquired 0 shares of Common Stock at $308.429 per share (Direct)
  Date: 2026-08-21 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,335.66 | transaction_form_type: 4 | Footnotes: F1
• Acquired 176 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,511.66 | transaction_form_type: 4 | Footnotes: F2, F2
• Acquired 168 shares of Common Stock (Direct)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,679.66 | transaction_form_type: 4 | Footnotes: F2, F2
• Sold 41 shares of Common Stock at $310.28 per share (Direct)
  Date: 2026-08-21 | Code: F | equity_swap_involved: 0 | shares_owned_after: 1,638.66 | transaction_form_type: 4 | Footnotes: F3
• Sold 43 shares of Common Stock at $310.28 per share (Direct)
  Date: 2026-08-21 | Code: F | equity_swap_involved: 0 | shares_owned_after: 1,595.66 | transaction_form_type: 4 | Footnotes: F3
• Sold 176 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 176.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2, F2, F2
• Sold 168 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 338.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2, F2, F2
• Acquired 172 shares of Phantom Stock Units (Derivative)
  Date: 2026-08-23 | Code: A | Expires: 2029-08-23 | Exercise: 2029-08-23 | equity_swap_involved: 0 | shares_owned_after: 172.00 | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Acquired 382 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-23 | Code: A | equity_swap_involved: 0 | shares_owned_after: 382.00 | transaction_form_type: 4 | Footnotes: F5, F5, F5, F5, F5
• Acquired 382 shares of Phantom Stock Units (Derivative)
  Date: 2026-08-23 | Code: A | Expires: 2029-08-23 | Exercise: 2029-08-23 | equity_swap_involved: 0 | shares_owned_after: 382.00 | transaction_form_type: 4 | Footnotes: F6, F6, F6
• Acquired 2,090 shares of Stock Option at $341.31 per share (Derivative)
  Date: 2026-08-23 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,090.00 | transaction_form_type: 4 | Footnotes: F7, F7, F7, F7

Footnotes:

• F1: Represents acquisition of stock pursuant to Company's Dividend Reinvestment Plan.
• F2: Vesting of Restricted Stock Units pursuant to the Company's 2018 Omnibus Incentive Plan.
• F3: Shares sold to pay taxes on vesting of previously issued restricted stock and/or performance share units.
• F4: Contingent Purchase of Phantom Stock of the Company pursuant to the Management Stock Purchase Plan component of the 2018 Omnibus Incentive Plan vesting three years after the date of purchase in the form of Common Stock.
• F5: Grant of Restricted Stock Units pursuant to the 2018 Omnibus Incentive Plan of the Company which vests one-third per year on each anniversary of the date of the award.
• F6: Award of Performance Share Units pursuant to the 2018 Omnibus Incentive Plan of the Company. These shares cliff vest at the end of a three year performance period with the ultimate number of shares ranging from 0 to 250% of the award based on achievement against Company performance metrics of the three year period.
• F7: Premium Priced Stock Option with exercise price 10% above the closing market price on the date of grant. Option vests 25% per year on each anniversary of the date of the award for four years. This option expires ten years from the date of grant.